A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes

DOI10.1111/biom.13347zbMath1520.62403WikidataQ98180688 ScholiaQ98180688MaRDI QIDQ6076490

No author found.

Publication date: 17 October 2023

Published in: Biometrics (Search for Journal in Brave)

zbMATH Keywords

adaptive designcompeting risktargeted therapyphase I/II clinical triallate-onset

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Unnamed Item
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
• Dose-Finding Designs for HIV Studies
• Continual Reassessment Method for Ordered Groups
• Robust EM Continual Reassessment Method in Oncology Dose Finding
• Design and Analysis of Phase I Clinical Trials
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
• Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
• The Calculation of Posterior Distributions by Data Augmentation
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

This page was built for publication: A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes